Metformin is a long-established prescription medication for type 2 diabetes that has attracted major longevity interest, with researchers studying whether its metabolic effects might have broader healthy-ageing benefits in people without diabetes. This longevity use is off-label and the subject of ongoing research, including the well-known TAME trial concept.
Metformin's safety and effect in diabetes are very well established over decades. Its longevity use in non-diabetics is genuinely being researched but is not established, and some evidence suggests it may blunt certain exercise adaptations, which complicates the picture for otherwise healthy, active people.
Well characterised in its approved use: commonly digestive side effects, and long-term use can affect vitamin B12 levels. Rare but serious lactic acidosis risk in specific circumstances (kidney impairment). Off-label use carries these known risks without established longevity benefit.
Legal and prescription status: metformin is prescription-only, and its longevity use is off-label and experimental. This is prescription-only medicine and must never be sourced or self-dosed outside a regulated prescription. Any use should be under a doctor's supervision with appropriate monitoring, including of B12 and kidney function.
Inexpensive as a prescription medication where indicated; off-label longevity use is typically arranged privately.
Extensive diabetes literature on metformin. Ongoing longevity research (TAME trial concept). Research on metformin and exercise adaptation. Educational information only. Prescription-only, off-label longevity use experimental.